188 related articles for article (PubMed ID: 35410461)
1. Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Borgognone A; Noguera-Julian M; Oriol B; Noël-Romas L; Ruiz-Riol M; Guillén Y; Parera M; Casadellà M; Duran C; Puertas MC; Català-Moll F; De Leon M; Knodel S; Birse K; Manzardo C; Miró JM; Clotet B; Martinez-Picado J; Moltó J; Mothe B; Burgener A; Brander C; Paredes R;
Microbiome; 2022 Apr; 10(1):59. PubMed ID: 35410461
[TBL] [Abstract][Full Text] [Related]
2. HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
Mothe B; Rosás-Umbert M; Coll P; Manzardo C; Puertas MC; Morón-López S; Llano A; Miranda C; Cedeño S; López M; Alarcón-Soto Y; Melis GG; Langohr K; Barriocanal AM; Toro J; Ruiz I; Rovira C; Carrillo A; Meulbroek M; Crook A; Wee EG; Miró JM; Clotet B; Valle M; Martinez-Picado J; Hanke T; Brander C; Moltó J;
Front Immunol; 2020; 11():823. PubMed ID: 32435247
[TBL] [Abstract][Full Text] [Related]
3. Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.
Duran-Castells C; Prats A; Oriol-Tordera B; Llano A; Galvez C; Martinez-Picado J; Ballana E; Garcia-Vidal E; Clotet B; Muñoz-Moreno JA; Hanke T; Moltó J; Mothe B; Brander C; Ruiz-Riol M
EBioMedicine; 2023 Sep; 95():104732. PubMed ID: 37506557
[TBL] [Abstract][Full Text] [Related]
4. Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.
Russo E; Nannini G; Sterrantino G; Kiros ST; Di Pilato V; Coppi M; Baldi S; Niccolai E; Ricci F; Ramazzotti M; Pallecchi M; Lagi F; Rossolini GM; Bartoloni A; Bartolucci G; Amedei A
World J Gastroenterol; 2022 Feb; 28(6):635-652. PubMed ID: 35317423
[TBL] [Abstract][Full Text] [Related]
5. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
[TBL] [Abstract][Full Text] [Related]
7. Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy.
Muñoz-Moreno JA; Carrillo-Molina S; Martínez-Zalacaín I; Miranda C; Manzardo C; Coll P; Meulbroek M; Hanke T; Garolera M; Miró JM; Brander C; Clotet B; Soriano-Mas C; Moltó J; Mothe B;
AIDS; 2022 Mar; 36(3):363-372. PubMed ID: 34750296
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
9. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
[TBL] [Abstract][Full Text] [Related]
10. The microbiome and HIV persistence: implications for viral remission and cure.
Koay WLA; Siems LV; Persaud D
Curr Opin HIV AIDS; 2018 Jan; 13(1):61-68. PubMed ID: 29135490
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe.
Burkhart Colorado AS; Lazzaro A; Neff CP; Nusbacher N; Boyd K; Fiorillo S; Martin C; Siebert JC; Campbell TB; Borok M; Palmer BE; Lozupone C
Microbiome; 2024 Feb; 12(1):18. PubMed ID: 38310301
[TBL] [Abstract][Full Text] [Related]
12. Impaired Nef function is associated with early control of HIV-1 viremia.
Kuang XT; Li X; Anmole G; Mwimanzi P; Shahid A; Le AQ; Chong L; Qian H; Miura T; Markle T; Baraki B; Connick E; Daar ES; Jessen H; Kelleher AD; Little S; Markowitz M; Pereyra F; Rosenberg ES; Walker BD; Ueno T; Brumme ZL; Brockman MA
J Virol; 2014 Sep; 88(17):10200-13. PubMed ID: 24965469
[TBL] [Abstract][Full Text] [Related]
13.
Rosás-Umbert M; Ruiz-Riol M; Fernández MA; Marszalek M; Coll P; Manzardo C; Cedeño S; Miró JM; Clotet B; Hanke T; Moltó J; Mothe B; Brander C;
Front Immunol; 2020; 11():418. PubMed ID: 32265913
[TBL] [Abstract][Full Text] [Related]
14. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
[TBL] [Abstract][Full Text] [Related]
15. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
[TBL] [Abstract][Full Text] [Related]
16. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
Puertas MC; Bayón-Gil Á; Garcia-Guerrero MC; Salgado M; Urrea V; Morón-López S; Peña R; Jiménez-Moyano E; Clotet B; Prado JG; Martinez-Picado J
mBio; 2021 Jun; 12(3):e0056021. PubMed ID: 34154408
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment controllers: what do they tell us?
Rouzioux C; Hocqueloux L; Sáez-Cirión A
Curr Opin HIV AIDS; 2015 Jan; 10(1):29-34. PubMed ID: 25402707
[TBL] [Abstract][Full Text] [Related]
18. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
[TBL] [Abstract][Full Text] [Related]
19. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.
Oriol-Tordera B; Esteve-Codina A; Berdasco M; Rosás-Umbert M; Gonçalves E; Duran-Castells C; Català-Moll F; Llano A; Cedeño S; Puertas MC; Tolstrup M; Søgaard OS; Clotet B; Martínez-Picado J; Hanke T; Combadiere B; Paredes R; Hartigan-O'Connor D; Esteller M; Meulbroek M; Calle ML; Sanchez-Pla A; Moltó J; Mothe B; Brander C; Ruiz-Riol M
EBioMedicine; 2022 Apr; 78():103956. PubMed ID: 35325780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
